AR077363A1 - DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS. - Google Patents
DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS.Info
- Publication number
- AR077363A1 AR077363A1 ARP100102347A ARP100102347A AR077363A1 AR 077363 A1 AR077363 A1 AR 077363A1 AR P100102347 A ARP100102347 A AR P100102347A AR P100102347 A ARP100102347 A AR P100102347A AR 077363 A1 AR077363 A1 AR 077363A1
- Authority
- AR
- Argentina
- Prior art keywords
- radical
- radicals
- alkyl
- optionally substituted
- chosen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Productos de formula (1): en la que: R1 representa un radical -L-arilo o -L-heteroarilo, tal que L representa: o bien simple enlace, o bien un radical alquilo lineal o ramificado que contiene 1 a 6 átomos de carbono y que está eventualmente sustituido con un radical hidroxilo, o bien un grupo CO o -CO-Alk-; o bien un grupo L'-X en donde L' representa un radical alquilo lineal o ramificado que contiene 1 a 6 átomos de carbono y X un átomo de oxígeno o de azufre; estando los radicales arilo y heteroarilo eventualmente sustituidos con uno o varios radicales idénticos o diferentes elegidos entre los átomos de halogeno y los radicales hidroxilo, CN, nitro, -COOH, -COOalk, -NRxRy, -CONRxRy, -NRxCORy, -NRxCO2Rz, CORy, alcoxi, fenoxi, alquiltio, alquilo, cicloalquilo y heterocicloalquilo; estando estos ultimos radicales alcoxi, fenoxi, alquiltio, alquilo y heterocicloalquilo sustituidos ellos mismos opcionalmente con uno o varios radicales idénticos o diferentes elegidos entre los átomos de halogeno y NRvRw; pudiendo contener, además, los radicales heterocicloalquilo y heteroarilo un radical oxo; R2 representa un átomo de hidrogeno o un radical alquilo; R3 representa un radical alquilo eventualmente sustituido con uno o varios átomos de halogeno; R4 representa un átomo de hidrogeno o un átomo de halogeno; siendo NRxRy tal que Rx representa un átomo de hidrogeno o un radical alquilo y Ry representa un átomo de hidrogeno, un radical cicloalquilo o un radical alquilo sustituido opcionalmente con uno o varios radicales idénticos o diferentes elegidos entre los radicales hidroxilo, alcoxi, NRvRw y heterocicloalquilo; o bien Rx y Ry forman con el átomo de nitrogeno al que están unidos un radical cíclico que comprende de 3 a 10 eslabones y opcionalmente uno o varios heteroátomos diferentes elegido(s) entre O, S, NH y N-alquilo, estando este radical cíclico eventualmente sustituido; siendo NRvRw tal que Rv representa un átomo de hidrogeno o un radical alquilo y Rw representa un átomo de hidrogeno, un radical cicloalquilo o un radical alquilo sustituido opcionalmente con uno o varios radicales idénticos o diferentes elegidos entre los radicales hidroxilo, alcoxi y heterocicloalquilo; o bien Rv y Rw forman con el átomo de nitrogeno al que están unidos un radical cíclico que comprende de 3 a 10 eslabones y opcionalmente uno o varios heteroátomos diferentes elegido(s) entre O, S, NH y N-alquilo, estando este radical cíclico eventualmente sustituido; los radicales cíclicos que pueden formar Rx y Ry o Rv y Rw respectivamente con el átomo de nitrogeno al que están unidos, están opcionalmente sustituidos con uno o varios radicales idénticos o diferentes elegidos entre los átomos de halogeno, los radicales alquilo, hidroxilo, oxo, alcoxi, NH2; NHalk y N(alk)2; Rz representa los valores de Ry a excepcion de hidrogeno; Rx, Ry y Rz en los radicales -NRxCORy, -CORy y NRxCO2Rz se eligen entre los significados indicados más arriba para Rx, Ry y Rz; todos los radicales alquilo (alk), alcoxi y alquiltio anteriores son lineales o ramificados y contienen de 1 a 6 átomos de carbono, estando dichos productos de formula (1) en todas las formas isomeras racémicas, enantiomeras y diastereoisomeras posibles, así como las sales por adicion de ácidos minerales y orgánicos o de bases minerales y orgánicas de dichos productos de formula (1).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0903237A FR2947551B1 (fr) | 2009-07-02 | 2009-07-02 | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a)pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
US24109809P | 2009-09-10 | 2009-09-10 | |
FR0957069A FR2951174B1 (fr) | 2009-10-09 | 2009-10-09 | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077363A1 true AR077363A1 (es) | 2011-08-24 |
Family
ID=43234240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102347A AR077363A1 (es) | 2009-07-02 | 2010-07-01 | DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS. |
Country Status (24)
Country | Link |
---|---|
US (1) | US8846670B2 (es) |
EP (1) | EP2448940B1 (es) |
JP (1) | JP5655070B2 (es) |
KR (1) | KR20120103553A (es) |
CN (1) | CN102482286B (es) |
AR (1) | AR077363A1 (es) |
AU (1) | AU2010267815B2 (es) |
BR (1) | BRPI1015943A8 (es) |
CA (1) | CA2766909C (es) |
DK (1) | DK2448940T3 (es) |
ES (1) | ES2487623T3 (es) |
HK (1) | HK1169388A1 (es) |
HR (1) | HRP20140786T1 (es) |
IL (1) | IL217293A (es) |
MX (1) | MX2012000103A (es) |
MY (1) | MY155661A (es) |
PL (1) | PL2448940T3 (es) |
PT (1) | PT2448940E (es) |
RU (1) | RU2561130C2 (es) |
SG (2) | SG10201403149YA (es) |
SI (1) | SI2448940T1 (es) |
TW (1) | TWI455940B (es) |
UY (1) | UY32754A (es) |
WO (1) | WO2011001113A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2655375B1 (fr) * | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
FR2969613B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one, leur preparation et leur utilisation pharmaceutique |
EA029473B1 (ru) | 2011-12-15 | 2018-03-30 | Новартис Аг | Применение ингибиторов pi3k для лечения острой и церебральной малярии |
FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
EP3266455B1 (en) | 2015-03-06 | 2020-12-30 | Korea Advanced Institute of Science and Technology | Composition for prevention or treatment of intractable epilepsy comprising mtor inhibitor |
US11077113B2 (en) | 2016-02-19 | 2021-08-03 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
PL3416957T3 (pl) | 2016-02-19 | 2021-02-08 | Sprint Bioscience Ab | Związki 6-heterocyklilo-4-morfolino-4-ylopirydyn-2-onu przydatne w leczeniu raka i cukrzycy |
WO2021222295A1 (en) * | 2020-04-27 | 2021-11-04 | Aruna Bio, Inc. | Binding agents and uses thereof for central nervous system delivery |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2703712A1 (de) | 1977-01-29 | 1978-08-03 | Bayer Ag | Substituierte pyrimidinon eckige klammer auf (di)-thio eckige klammer zu -phosphor-(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide, akarizide und nematizide |
MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
NZ520300A (en) | 2000-01-24 | 2004-05-28 | Kinacia Pty Ltd | Morpholino-substituted pyridopyrimidine, quinolone and benzopyranone derivatives that inhibit the enzyme phosphoinositide (PI) 3-kinase |
EP1315731B1 (en) * | 2000-09-01 | 2004-06-16 | Sanofi-Synthelabo | 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
DK1430057T3 (da) * | 2001-09-21 | 2006-01-16 | Sanofi Aventis | Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater |
EP1340761A1 (en) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives |
AU2003221500B9 (en) * | 2002-02-28 | 2008-11-20 | Mitsubishi Pharma Corporation | Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl -6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
JP4646626B2 (ja) | 2002-08-16 | 2011-03-09 | アストラゼネカ アクチボラグ | ホスホイノシチド3−キナーゼβの阻害 |
PL377354A1 (pl) * | 2002-12-27 | 2006-01-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4H-pirydo[1,2-a]pirymidyny i związki pokrewne użyteczne jako inhibitory integrazy HIV |
EP1454909B1 (en) | 2003-03-07 | 2008-08-20 | Sanofi Aventis | 8'-pyridinyl-dihydrospiro (cycloalkyl) -pyrimido (1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro (cycloalkyl) pyrimido (1,2-a) pyrimidin-6 derivatives -one and their use against neurodegenerative diseases |
EP1460076A1 (en) | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
EP1557417B1 (en) | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
AR054438A1 (es) | 2005-04-15 | 2007-06-27 | Kudos Pharm Ltd | Inhibidores de adn -pk |
JP2008542253A (ja) * | 2005-05-26 | 2008-11-27 | クドス ファーマシューティカルズ リミテッド | Dna損傷癌療法に対してatm欠損癌を感作するためのdna−pk阻害の使用 |
WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
WO2008148074A2 (en) * | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
-
2010
- 2010-07-01 RU RU2012103477/04A patent/RU2561130C2/ru not_active IP Right Cessation
- 2010-07-01 CN CN201080039109.6A patent/CN102482286B/zh not_active Expired - Fee Related
- 2010-07-01 CA CA2766909A patent/CA2766909C/fr not_active Expired - Fee Related
- 2010-07-01 DK DK10742013.5T patent/DK2448940T3/da active
- 2010-07-01 MY MYPI2011006391A patent/MY155661A/en unknown
- 2010-07-01 PL PL10742013T patent/PL2448940T3/pl unknown
- 2010-07-01 BR BRPI1015943A patent/BRPI1015943A8/pt not_active IP Right Cessation
- 2010-07-01 AU AU2010267815A patent/AU2010267815B2/en not_active Ceased
- 2010-07-01 SG SG10201403149YA patent/SG10201403149YA/en unknown
- 2010-07-01 US US13/381,790 patent/US8846670B2/en not_active Expired - Fee Related
- 2010-07-01 ES ES10742013.5T patent/ES2487623T3/es active Active
- 2010-07-01 EP EP10742013.5A patent/EP2448940B1/fr active Active
- 2010-07-01 KR KR1020127002806A patent/KR20120103553A/ko active IP Right Grant
- 2010-07-01 SG SG2011097839A patent/SG177464A1/en unknown
- 2010-07-01 SI SI201030717T patent/SI2448940T1/sl unknown
- 2010-07-01 PT PT107420135T patent/PT2448940E/pt unknown
- 2010-07-01 AR ARP100102347A patent/AR077363A1/es unknown
- 2010-07-01 WO PCT/FR2010/051374 patent/WO2011001113A2/fr active Application Filing
- 2010-07-01 JP JP2012518119A patent/JP5655070B2/ja not_active Expired - Fee Related
- 2010-07-01 MX MX2012000103A patent/MX2012000103A/es active IP Right Grant
- 2010-07-02 UY UY0001032754A patent/UY32754A/es not_active Application Discontinuation
- 2010-07-02 TW TW099121933A patent/TWI455940B/zh not_active IP Right Cessation
-
2011
- 2011-12-29 IL IL217293A patent/IL217293A/en not_active IP Right Cessation
-
2012
- 2012-10-08 HK HK12109830.1A patent/HK1169388A1/xx not_active IP Right Cessation
-
2014
- 2014-08-20 HR HRP20140786AT patent/HRP20140786T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077363A1 (es) | DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS. | |
AR077446A1 (es) | Derivados de 2,3-dihidro-1h-imidazo(1,2-a) pirimidin-5-ona. su preparacion y su utilizacion farmaceutica | |
AR077364A1 (es) | Derivados de 6-oxo-1,6- dihidro -pirimidin-2-il-) amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb) | |
AR073136A1 (es) | Compuestos de pirrol | |
UY30105A1 (es) | Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas. | |
NI200900037A (es) | Derivados de 2-aril-6-fenil-imidazo[1,2-alfa] piridinas, su preparación y su aplicación en terapéutica. | |
AR072518A1 (es) | Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met." | |
AR064730A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
UY30104A1 (es) | Derivados nuevos de urea ciclica, su preparacinn y su utilizacinn farmacéutica como inhibidores de cinasas | |
EA201170096A1 (ru) | Замещенные производные пиримидона | |
AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
AR064729A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
AR068912A1 (es) | Derivados de 6- aril/ heteroarilquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y utilizacion como inhibidores de cmet | |
ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
AR091498A1 (es) | DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
CU23761B7 (es) | Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CO6341610A2 (es) | Compuesto heterociclilo aromatico que contiene nitrogeno. | |
AR068056A1 (es) | Derivados de n, n'-2, 4 - dianilinopirimidinas, su preparacion, su uso como medicamentos, composiciones farmaceuticas y especialmente como inhibidores de ikk. | |
AR067062A1 (es) | Una composicion de resina, un recubrimiento antiincrustante y procesos para su produccion | |
CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
AR066605A1 (es) | Derivados de heteroarilamida pirimidona | |
AR077510A1 (es) | Derivados de dihidroindolonas, su procedimiento de preparacion y las com-posiciones farmaceuticas que los contienen | |
CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
AR075251A1 (es) | Derivados de 6-(6-sustituido-triazolopiridazina-sulfanil)-5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles, metodo de preparacion e intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del cancer y otros trastorno hiperproliferativos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |